← Leaderboards
Mark A Beilke
Tulane University Of Louisiana
$2,541,648
Attributed
$2,541,648
Total exposure
14
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $543.6K · FY2005–12$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$2,541,648 · 13
VA$0 · 1
By mechanism
R01$1,712,774 · 1
P51$472,374 · 8
M01$356,500 · 4
I01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- Laura S Levy$4,511,732
- Bruce A Barron$403,354
- Paul J Brindley$8,968,834
- Kathleen S Hering-Smith$1,893,678
- Khalid Matrougui$5,557,211
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusAidsHuman T Cell Lymphotropic Virus Type 1Virus LoadHuman T Cell Lymphotropic Virus Type 2Drug AbusePathologic ProcessReportingPolymerase Chain ReactionHuman T-Lymphotropic Virus 2Clinical ResearchPeripheral Blood Mononuclear CellImmunologyT-Lymphocyte SubsetsInfectionHelper T LymphocyteEnrollmentHiv-1Cytotoxic T LymphocyteHuman SubjectHuman T-Lymphotropic Virus 1Aids /Hiv NeuropathyDisease /Disorder Proneness /RiskChemokine
Grant awards (26)
Immunomodulatory Function of Human T Cell Leukemia Virus Type 2 (HTLV-2)$0
I01 · FY2012 · VA · contact PI
Immunomodulatory Function of Human T Cell Leukemia Virus Type 2 (HTLV-2)$0
I01 · FY2011 · VA · contact PI
Immunomodulatory Function of Human T Cell Leukemia Virus Type 2 (HTLV-2)$0
I01 · FY2011 · VA · contact PI
HIV, HTLV AND DRUG ABUSE$63,253
P51 · FY2008 · RR · contact PI
HIV, HTLV AND DRUG ABUSE$71,638
P51 · FY2007 · RR · contact PI
Retroviral Co-Infections: HIV, HTLV and Drug Abuse$196,825
R01 · FY2006 · AI · contact PI
Retroviral Co-Infections: HIV, HTLV and Drug Abuse$129,449
R01 · FY2006 · AI · contact PI
RETROVIRAL CO-INFECTIONS: HIV, HTLV AND DRUG ABUSE$94,293
M01 · FY2006 · RR · contact PI
HIV, HTLV AND DRUG ABUSE$65,435
P51 · FY2006 · RR · contact PI
Retroviral Co-Infections: HIV, HTLV and Drug Abuse$334,125
R01 · FY2005 · AI
RETROVIRAL CO-INFECTIONS: HIV, HTLV AND DRUG ABUSE$100,497
M01 · FY2005 · RR
EXPERIMENTAL TRANSMISSION OF HTLV-I TO NONHUMAN PRIMATE$54,500
P51 · FY2005 · RR
HIV, HTLV AND DRUG ABUSE$54,500
P51 · FY2005 · RR
Retroviral Co-Infections: HIV, HTLV and Drug Abuse$334,125
R01 · FY2004 · AI
Retroviral Co-Infections: HIV, HTLV and Drug Abuse$139,350
M01 · FY2004 · RR
EXPERIMENTAL TRANSMISSION OF HTLV-I TO NONHUMAN PRIMATE$47,161
P51 · FY2004 · RR
Retroviral Co-Infections: HIV, HTLV and Drug Abuse$359,125
R01 · FY2003 · AI
EXPERIMENTAL TRANSMISSION OF HTLV-I TO NONHUMAN PRIMATE$61,560
P51 · FY2003 · RR
Retroviral Co-Infections: HIV, HTLV and Drug Abuse$359,125
R01 · FY2002 · AI
EXPERIMENTAL TRANSMISSION OF HTLV I TO NON HUMAN PRIMATE$0
P51 · FY2002 · RR
EXPERIMENTAL TRANSMISSION OF HTLV I TO NON HUMAN PRIMATE$0
P51 · FY2001 · RR
MONITORING CMV VIRAL LOADS$0
M01 · FY2001 · RR
GULF SOUTH RETROVIRAL COINFECTION CLINIC$0
M01 · FY2001 · RR
EXPERIMENTAL TRANSMISSION OF HTLV I TO NON HUMAN PRIMATE$54,327
P51 · FY2000 · RR
MONITORING CMV VIRAL LOADS$11,180
M01 · FY2000 · RR
GULF SOUTH RETROVIRAL COINFECTION CLINIC$11,180
M01 · FY2000 · RR